Order Online! Now! Get your $50 coupon for online order.Order Online! Now! Get your $50 coupon for online order.
Cancer Prevention Month: Get ACRO Health Gift Cards! Cancer Prevention Month: Get ACRO Health Gift Cards!
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Fill out organ-on-a-chip questionnaire to win a FREE gift! Fill out organ-on-a-chip questionnaire to win a FREE gift!
Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
FLT3 Inhibition | Small molecule | Oncology/Cancer | AML | Phase III | Global |
FMS-like tyrosine kinase 3(FLT3)inhibitor | Small molecule | Oncology/Cancer | Advanced/Metastatic Malignant Solid Tumors,Relapsed/Refractory Acute Myeloid Leukemia with FLT3 Mutation | Phase III | Global |
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
FL3-C52H5 | Cynomolgus | Cynomolgus Flt-3 / Flk-2 Protein, His Tag (MALS verified) |
|
|
|
FL3-HF255 | Human | FITC-Labeled Human Flt-3 / Flk-2 Protein, Fc Tag |
|
|
|
FL3-H82E3 | Human | Biotinylated Human Flt-3 / Flk-2 Protein, His,Avitag™ (MALS verified) |
|
|
|
FL3-H52H6 | Human | Human Flt-3 / Flk-2 Protein, His Tag (MALS verified) |
|
|
|
FL3-M52H6 | Mouse | Mouse Flt-3 / Flk-2 Protein, His Tag |
|
||
FL3-H5258 | Human | Human Flt-3 / Flk-2 Protein, Fc Tag (MALS verified) |
|
|
Immobilized Human Flt-3 Ligand, premium grade (Cat. No. FLL-H5218) at 1 μg/mL (100 μL/well) can bind FITC-Labeled Human Flt-3, Fc Tag (Cat. No. FL3-HF255) with a linear range of 0.2-13 ng/mL (QC tested).
The purity of Cynomolgus Flt-3 Protein, His Tag (Cat. No. FL3-C52H5) is more than 90% and the molecular weight of this protein is around 75-95 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Midostaurin | PKC-412; PKC-412A; CGP-41231; CGP-41251 | Approved | Novartis Pharma Ag | Rydapt | United States | Mastocytosis, Systemic; Leukemia, Mast-Cell; Hematologic Neoplasms; Leukemia, Myeloid, Acute | Novartis Pharmaceuticals Corp | 2017-04-28 | Leukemia; Hematologic Neoplasms; Mastocytosis, Systemic; Myelodysplastic Syndromes; Leukemia, Mast-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Mastocytosis | Details |
pacritinib citrate | SB-1518; ONX-0803 | Approved | S*BIO Pte Ltd, Concert | VONJO | United States | Primary Myelofibrosis | Cti Biopharma Corp | 2022-02-28 | Hepatic Insufficiency; Carcinoma, Non-Small-Cell Lung; Thrombocythemia, Essential; Leukemia, Lymphocytic, Chronic, B-Cell; Sarcoma, Kaposi; Thrombocytopenia; Lymphoma, T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Myelomonocytic, Juvenile; Lymphoma, T-Cell, Cutaneous; Leukemia, Myeloid, Acute; Waldenstrom Macroglobulinemia; Colorectal Neoplasms; Lymphoproliferative Disorders; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Lymphoma, T-Cell, Peripheral; Primary Myelofibrosis; Castleman Disease; Coronavirus Infections; Lymphoma, Mantle-Cell; Myelodysplastic Syndromes; Coronavirus Disease 2019 (COVID-19); Graft vs Host Disease; Hodgkin Disease; Myeloproliferative Disorders; Leukemia, Myelomonocytic, Chronic; Polycythemia Vera; Lymphoma, B-Cell; Leukemia, Myelogenous, Chronic; Leukemia | Details |
Sunitinib Malate | PHA-290940; SU-010398; SU-11248; GB-102; PNU-290940; SU-011248-L-malate salt; PNU-290940AD; PHA-290940AD; SCAI-003 | Approved | Pfizer Pharmaceuticals Ltd (China) | Sutent, 索坦 | United States | Gastrointestinal Stromal Tumors; Carcinoma, Renal Cell | Cppi Cv | 2006-01-26 | Solid tumours; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Leiomyosarcoma; Fibrosarcoma; Leukemia; Kidney Neoplasms; Teratoma; Head and Neck Neoplasms; HIV Infections; Intestinal Neoplasms; Ovarian Neoplasms; Ependymoma; Leukemia, Myeloid, Accelerated Phase; Fibromatosis, Aggressive; Liver Neoplasms; Lymphoma, T-Cell, Peripheral; Leukemia, Myelogenous, Chronic; Carcinoma, Renal Cell; Pheochromocytoma; Histiocytoma, Malignant Fibrous; Thoracic Neoplasms; Hemangioblastoma; Leukemia, Hairy Cell; Abdominal Neoplasms; Stomach Neoplasms; Carcinoma, Islet Cell; Polycythemia Vera; Esophageal Neoplasms; Carcinoma; Pelvic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Glioblastoma; Myelodysplastic Syndromes; Carcinoma, Papillary; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Leukemia, Myelomonocytic, Chronic; Neurofibromatoses; Pancreatic neuroendocrine tumors (pNET); Neoplasms; Adenoma, Islet Cell; Myeloproliferative Disorders; Pancreatic Neoplasms; Plasmacytoma; Carcinoma, Transitional Cell; Immunogl | Details |
Brigatinib | AP-26113 | Approved | Ariad Pharmaceuticals Inc | Alunbrig, ALUNBRIG | United States | Carcinoma, Non-Small-Cell Lung | Takeda Pharmaceuticals U.S.A. Inc | 2017-04-28 | Solid tumours; Ependymoma; Carcinoma; Neoplasms; Neurofibromatosis 2; Myofibroma; Lung Neoplasms; Brain metastases; Granuloma, Plasma Cell; Lymphoma, Large-Cell, Anaplastic; Carcinoma, Non-Small-Cell Lung; Sarcoma, Kaposi; Neuroma, Acoustic; Meningioma; Neurilemmoma | Details |
Cabozantinib S-malate | XL-184; BMS-907351 | Approved | Exelixis Inc | Cometriq, Cabometyx | United States | Carcinoma, Neuroendocrine; Thyroid Neoplasms | Exelixis Inc | 2012-11-29 | Carcinoma, Adenosquamous; Uterine Neoplasms; Thyroid Neoplasms; Hepatic Insufficiency; Gliosarcoma; Bile Duct Neoplasms; Peritoneal Neoplasms; Astrocytoma; Colorectal Neoplasms; Brain Neoplasms; Endometrial Neoplasms; Osteosarcoma; Urethral Neoplasms; Adenocarcinoma, Clear Cell; Neuroblastoma; Neurofibroma, Plexiform; Cholangiocarcinoma; Medullary thyroid cancer (MTC); Sarcoma, Ewing; Breast Neoplasms; Carcinoma, Endometrioid; Neoplasms, Germ Cell and Embryonal; Meningioma; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Thyroid Cancer, Papillary; Neoplasm Metastasis; Paraganglioma; Carcinoma, Hepatocellular; Sarcoma, Clear Cell; Carcinoma, Neuroendocrine; Fallopian Tube Neoplasms; Brain metastases; Lymphoma; Leukemia, Myeloid, Acute; Sarcoma, Alveolar Soft Part; Glioma; Carcinoma, Squamous Cell; Pain; Adrenal Cortex Neoplasms; Pancreatic neuroendocrine tumors (pNET); Glioblastoma; Kidney Diseases; Hepatoblastoma; Pheochromocytoma; Carcinoma, Renal Cell; Rejection of liver transplantation; Carcinoid | Details |
Fedratinib | TG-101348; SAR-302503 | Approved | Sanofi | Inrebic | United States | Primary Myelofibrosis | Impact Biomedicines | 2019-08-16 | Hematologic Neoplasms; Solid tumours; Polycythemia Vera; Kidney Diseases; Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Leukemia, Neutrophilic, Chronic; Primary Myelofibrosis; Hepatic Insufficiency; Splenomegaly; Thrombocythemia, Essential | Details |
Pexidartinib | PLX-3397 | Approved | Daiichi Sankyo Co Ltd | Turalio | United States | Giant Cell Tumor of Tendon Sheath | Daiichi Sankyo Inc | 2019-08-02 | Neurofibrosarcoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasm Metastasis; Leukemia, Myeloid, Acute; Gastrointestinal Stromal Tumors; Colorectal Neoplasms; Giant Cell Tumors; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Neurofibroma, Plexiform; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms; Sarcoma; Solid tumours; Breast Neoplasms; Neoplasms; Arthritis, Rheumatoid; Hodgkin Disease; Glioblastoma; Pancreatic Neoplasms; Synovitis, Pigmented Villonodular; Squamous Cell Carcinoma of Head and Neck; Leukemia, Promyelocytic, Acute; Ovarian Neoplasms; Giant Cell Tumor of Tendon Sheath | Details |
Vorolanib | X-82; EYP-1901; CM-082 | Approved | Tyrogenex Inc | 伏美纳 | Mainland China | Carcinoma, Renal Cell | Betta Pharmaceuticals Co Ltd | 2023-06-07 | Diabetic macular oedema; Diabetic Retinopathy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Macular Degeneration; Choroidal Neovascularization; Adenocarcinoma; Leukemia, Myeloid, Acute; Retinal Degeneration; Eye Diseases; Solid tumours; Wet Macular Degeneration; Retinal Diseases; Small Cell Lung Carcinoma; Neoplasms; Pancreatic Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Kidney Neoplasms | Details |
Nintedanib Esylate | BIBF-1120 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Ofev, Vargatef | United States | Idiopathic Pulmonary Fibrosis | Boehringer Ingelheim Gmbh | 2014-10-15 | Carcinoma, Squamous Cell; Sarcoma; Prostatic Neoplasms; systemic sclerosis-associated interstitial lung disease; Adenocarcinoma, Clear Cell; Colorectal Neoplasms; Peritoneal Neoplasms; Astrocytoma; Genital Neoplasms, Female; Hepatic Insufficiency; Silicosis; Gliosarcoma; Breast Neoplasms; Lung Neoplasms; Appendiceal Neoplasms; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Uterine Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Carcinoma, Endometrioid; Adenocarcinoma; Glioblastoma; Telangiectasia, Hereditary Hemorrhagic; Solid tumours; Radiation Pneumonitis; Esophageal Neoplasms; Rejection of lung transplantation; Carcinoma, Renal Cell; Carcinoid Tumor; Endometrial Stromal Tumors; Colonic Neoplasms; Idiopathic Pulmonary Fibrosis; Ovarian Neoplasms; Scleroderma, Systemic; Neoplasms; Small Cell Lung Carcinoma; Lung Diseases, Interstitial; Mesothelioma; Pulmonary Fibrosis; Multiple Myeloma; Asbestosis; Oligodendroglioma; Neuroendocrine Tumors | Details |
Ponatinib Hydrochloride | AP24534 hydrochloride; AP24534-HCL; AP24534 HCl; INCB-84344; AP-24534 | Approved | Ariad | Iclusig | United States | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic | Ariad Pharmaceuticals Inc | 2012-12-14 | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Biphenotypic, Acute; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Lymphoma; Leukemia, Myeloid, Acute; Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Chronic-Phase; Philadelphia Chromosome; Common Bile Duct Neoplasms; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Medullary thyroid cancer (MTC); Leukemia, Myelogenous, Chronic; Blast Crisis; Glioblastoma; Leukemia, Myelomonocytic, Chronic; Adenocarcinoma of Lung; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Hematologic Neoplasms; Leukemia, Myeloid, Accelerated Phase; Leukemia; Head and Neck Neoplasms | Details |
Quizartinib | AC-010220; ASP-2689; AC-220 | Approved | Ambit Biosciences Co | Vanflyta | Japan | Leukemia, Myeloid, Acute | Daiichi Sankyo Co Ltd | 2019-06-18 | Leukemia; Leukemia, Myeloid; Solid tumours; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute | Details |
Gilteritinib Fumarate | ASP-2215 hemifumarate; ASP-2215; 66D-92MGC8M (UNII code) | Approved | Astellas Pharma Inc | Xospata | Japan | Leukemia, Myeloid, Acute | Astellas Pharma Inc | 2018-09-21 | Solid tumours; Renal Insufficiency; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung | Details |
Sorafenib Tosylate | NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 | Approved | Onyx Pharmaceuticals Inc | Nexavar, 多吉美 | United States | Carcinoma, Renal Cell | Bayer Healthcare Pharmaceuticals Inc | 2005-12-01 | Liver Neoplasms; Leiomyosarcoma; Solid tumours; Recurrence; Ovarian Neoplasms; Leukemia, Erythroblastic, Acute; Rhabdomyosarcoma; Leukemia, Myelogenous, Chronic; Head and Neck Neoplasms; Lymphoma, T-Cell, Peripheral; Fibromatosis, Aggressive; Kidney Neoplasms; Lymphoma, B-Cell, Marginal Zone; Leukemia, Myeloid; Carcinoma, Renal Cell; Histiocytoma, Malignant Fibrous; Carcinoma; Hemangiosarcoma; Carcinoid Tumor; Stomach Neoplasms; Insulinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Islet Cell; Esophageal Neoplasms; Rectal Neoplasms; Vipoma; Myelodysplastic Syndromes; Neoplasms; Wilms Tumor; Thyroid Carcinoma, Anaplastic; Kidney Diseases; Carcinoma, Transitional Cell; Carcinoma, Verrucous; Small Cell Lung Carcinoma; Lymphoma, Large-Cell, Immunoblastic; Salivary Gland Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphomatoid Granulomatosis; Multiple Endocrine Neoplasia Type 2a; Glioblastoma; Carcinoma, Ovarian Epithelial; Leukemia, Myelomonocytic, Acute; Colonic Neoplasms; Leukemia, Myelomonocytic, Ch | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
MAX-40279 | MAX-40279-001; Max-40279; MAX-40279-01; MAX-4 | Phase 2 Clinical | Maxinovel Pharmaceuticals Co Ltd | Solid tumours; Leukemia; Esophageal Neoplasms; Stomach Neoplasms; Idiopathic Pulmonary Fibrosis; Myelodysplastic Syndromes; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Neoplasm Metastasis | Details |
EP-0042 | EP-0042 | Phase 2 Clinical | Ellipses Pharma | Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
SKI-G-801 | G-801; SKI-G-801; G-749 Hydrochloride | Phase 1 Clinical | Oscotec Inc | Solid tumours; Leukemia, Myeloid, Acute | Details |
SENTI-202 | SENTI-202 | Phase 1 Clinical | Senti Biosciences Inc | Hematologic Neoplasms; Leukemia, Myeloid, Acute | Details |
Flysyn | 4G8-SDIEM | Phase 2 Clinical | Synimmune Gmbh | Leukemia, Myeloid, Acute | Details |
Fms-like tyrosine kinase 3 ligand (Celldex Therapeutics) | CDX-301 | Phase 2 Clinical | Amgen Inc | Sarcoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma; Leukemia, Myeloid, Acute; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Osteosarcoma; Skin Melanoma; Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Myelodysplastic Syndromes; Hodgkin Disease; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Leukemia, Myelogenous, Chronic | Details |
Merestinib | 5OGS5K699E; LY-2801653 | Phase 2 Clinical | Eli Lilly And Company | Biliary Tract Neoplasms; Skin Melanoma; Bone metastases; Solid tumours; Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Breast Neoplasms; Lymphoma, Mantle-Cell; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Gallbladder Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
HEC-73543 | HEC-73543 | Phase 3 Clinical | Hec Pharm Co Ltd | Leukemia, Myeloid, Acute | Details |
Glesatinib | MGCD-265; MG-90265X; 7Q29OXD98N; MG-90265H9; MG-90265gly; MG-90265 | Phase 2 Clinical | Mirati Therapeutics Inc | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
QBH-196 | QBH-196 | Phase 1 Clinical | Shenyang Pharmaceutical University | Solid tumours; Stomach Neoplasms | Details |
FN-1501 | FN-1501; LT-171-861 | Phase 2 Clinical | China Pharmaceutical University, Shanghai Fosun Pharmaceutical Industrial Development Co Ltd | Solid tumours; Neoplasms; Leukemia, Myeloid, Acute; Carcinoma, Hepatocellular | Details |
ZE46-0134 | ZE46-0134; ZE-46-0134 | Phase 1 Clinical | Eilean Therapeutics LLC | Leukemia, Promyelocytic, Acute | Details |
Crenolanib Besylate | CP-868596-26; IND-112201; CP-868596; ARO-002; ARO-002-26 | Phase 3 Clinical | Pfizer Pharmaceuticals Ltd (China) | Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Acute; Glioma | Details |
Tuspetinib | HM-43239 | Phase 2 Clinical | Hanmi Pharmaceutical Co Ltd | Leukemia, Myeloid, Acute | Details |
Mivavotinib | TAK-659; CB-659 | Phase 1 Clinical | Takeda Pharmaceutical Co Ltd | Lymphoma, B-Cell; Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Plasmablastic Lymphoma; Lymphoma, Follicular; Lymphoma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
ETH-155008 | ETH-155008 | Phase 1 Clinical | Yunnan Shengke Pharmaceutical Co Ltd | Leukemia; Leukemia, Promyelocytic, Acute; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute | Details |
Emirodatamab | AMG-427 | Phase 1 Clinical | Amgen Inc | Leukemia, Myeloid, Acute | Details |
TT-00973 | TT-00973 | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Solid tumours | Details |
Anti-FLT3 CAR-T Cell Therapy (PersonGen Biomedicine) | TAA05 | Phase 2 Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Leukemia, Myeloid, Acute | Details |
XY0206 | XY-0206 | Phase 3 Clinical | Shijiazhuang Yiling Pharmaceutical Co Ltd, Nanjing University Of Chinese Medicine | Solid tumours; Leukemia, Myeloid, Acute | Details |
Nintedanib Solution for Inhalation | AP02; AP-02 | Phase 1 Clinical | Avalyn Pharma Inc | Idiopathic Pulmonary Fibrosis | Details |
Zotiraciclib | TG-02; SB-1317 | Phase 2 Clinical | Syncore Biotechnology Co Ltd | Glioblastoma; Neoplasms; Brain Neoplasms; Astrocytoma; Gliosarcoma; Glioma; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Hepatocellular | Details |
KC1036 | KC1036; KC-1036 | Phase 3 Clinical | Beijing Konruns Pharmaceutical Co Ltd | Hematologic Neoplasms; Solid tumours; Digestive System Neoplasms; Sarcoma, Ewing; Thymus Neoplasms; Esophageal Squamous Cell Carcinoma; Adenocarcinoma; Neoplasm Metastasis | Details |
Ningetinib Tosylate | CT-053-PTSA; CT-053 | Phase 2 Clinical | Hec Pharm Co Ltd | Intestinal Neoplasms; Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
LNK-01002 | LNK01002 | Phase 1 Clinical | Lynk Pharmaceutical (Hangzhou) Co Ltd | Hematologic Neoplasms; Polycythemia Vera; Myeloproliferative Disorders; Primary Myelofibrosis; Leukemia, Myeloid, Acute | Details |
Emavusertib | CA-4948; AU-4948 | Phase 2 Clinical | Aurigene | Anemia; Esophageal Neoplasms; Stomach Neoplasms; Myelodysplastic Syndromes; Pancreatic Neoplasms; Digestive System Neoplasms; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Carcinoma, Pancreatic Ductal; Melanoma; Gastrointestinal Neoplasms | Details |
SEL-24 | SEL-24 program; SEL-24; MEN-1703; SEL-24-1; SEL-24-B489 | Phase 2 Clinical | Selvita | Leukemia, Myeloid, Acute | Details |
ETH-155036 | ETH-155036; ETH155036 | Phase 1 Clinical | Shengke Pharmaceutical (Jiangsu) Co Ltd | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
CLN-049 | CLN-049 | Phase 1 Clinical | University Of Tubingen, German Cancer Research Center (Dkfz) | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Clifutinib Besylate | Phase 3 Clinical | Guangdong Dongyangguang Pharmaceutical Co Ltd | Leukemia, Myeloid, Acute | Details | |
SKLB-1028 | SKLB-1028 | Phase 3 Clinical | Sichuan University, CSPC Pharmaceutical Group Ltd | Solid tumours; Leukemia, Promyelocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute | Details |
Luxeptinib | CG-806; CG-026806 | Phase 1 Clinical | Crystalgenomics Inc, Aptose | Myelodysplastic Syndromes; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Sorafenib/MG-005 | MG-D-1509; MGD-1509 | Tri-Service General Hospital, Metagone Biotech Inc | Details | ||
Flonoltinib maleate | Phase 2 Clinical | Chengdu Zenitar Biomedical Technology Co Ltd | Polycythemia Vera; Alopecia Areata; Myeloproliferative Disorders; Primary Myelofibrosis; Lymphohistiocytosis, Hemophagocytic; Thrombocythemia, Essential | Details | |
Sorafenib Tosylate/Comekibart | MG-D-1609 | Phase 2 Clinical | Metagone Biotech Inc | Solid tumours | Details |
HYML-122 | HYML-122; CHMFL-FLT3-122 | Phase 2 Clinical | Hefei Academy Of Physical Sciences, Chinese Academy Of Sciences, Hefei Cosource Pharmaceuticals | Leukemia, Myeloid, Acute | Details |
FF-10101 | FF-10101; FF-10101-01; FF-10101 succinate | Phase 2 Clinical | Fujifilm Corp | Leukemia, Myeloid, Acute | Details |
NMS-03592088 | NMS-P088; NMS-03592088 | Phase 2 Clinical | Nerviano Medical Sciences Srl | Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute | Details |
MRX-2843 | MRX-2843; UNC-2025; UNC-2371 | Phase 2 Clinical | Meryx Inc, University Of North Carolina At Chapel Hill, University Of Colorado At Denver | Leukemia; Solid tumours; Neoplasms; Pathologic Processes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Lung Neoplasms; Neoplastic Processes; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
Lestaurtinib | SPM-924; A-154475.0; KT-5555; SP-924; CEP-701 | Phase 3 Clinical | Kyowa Hakko Kirin Co Ltd | Leukemia, Myeloid; Bone Marrow Neoplasms; Leukemia; Polycythemia Vera; Prostatic Neoplasms; Psoriasis; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neuroblastoma; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Thrombocythemia, Essential | Details |
LM-061 | LM-061 | Phase 1 Clinical | Shanghai Lixin Pharmaceutical Research and Development Co Ltd | Solid tumours | Details |
E-6201 | E-6201 | Phase 1 Clinical | Eisai Co Ltd | Solid tumours; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Psoriasis; Brain metastases; Leukemia, Myeloid, Acute; Melanoma | Details |
BMF-500 | BMF-500 | Phase 1 Clinical | Biomea Fusion Inc | Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
This web search service is supported by Google Inc.